Bindarit inhibits the synthesis of MCP-1, targeting inflammation in conditions like atherosclerosis and certain cancers, while Risperidone, an antipsychotic, may interact with CCL2 by modulating immune-related side effects rather than through direct evidence. These drug-gene interactions primarily affect pharmacodynamic aspects, influencing treatment effectiveness by altering inflammation related to MCP-1.